| Neil J Martin, MD | |
|
10706 E Us Highway 36, Avon, IN 46123-7982 | |
| (317) 271-3600 | |
| (317) 271-3604 |
| Full Name | Neil J Martin |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 36 Years |
| Location | 10706 E Us Highway 36, Avon, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689749178 | NPI | - | NPPES |
| 200048850A | Medicaid | IN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Daviess Community Hospital | Washington, IN | Hospital |
| Saint Joseph Regional Medical Center - Plymouth | Plymouth, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Great Lakes Anesthesia Pc | 0648183442 | 11 |
| Daviess County Hospital | 1557271665 | 65 |
News Archive
Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion.
Neuroblastoma is among the most common of childhood cancers and fortunately, some children will get better spontaneously. Yet for children with high-risk disease the outlook is poor: more than half will relapse despite chemotherapy.
Tim Dupin thought — or at least hoped — that Missouri firefighters, paramedics and other emergency medical services personnel would be among the first to get vaccinated against the coronavirus.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
› Verified 4 days ago
| Entity Name | Great Lakes Anesthesia Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720039977 PECOS PAC ID: 0648183442 Enrollment ID: O20041115001189 |
News Archive
Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion.
Neuroblastoma is among the most common of childhood cancers and fortunately, some children will get better spontaneously. Yet for children with high-risk disease the outlook is poor: more than half will relapse despite chemotherapy.
Tim Dupin thought — or at least hoped — that Missouri firefighters, paramedics and other emergency medical services personnel would be among the first to get vaccinated against the coronavirus.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
› Verified 4 days ago
| Entity Name | Daviess County Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124231493 PECOS PAC ID: 1557271665 Enrollment ID: O20100420000663 |
News Archive
Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion.
Neuroblastoma is among the most common of childhood cancers and fortunately, some children will get better spontaneously. Yet for children with high-risk disease the outlook is poor: more than half will relapse despite chemotherapy.
Tim Dupin thought — or at least hoped — that Missouri firefighters, paramedics and other emergency medical services personnel would be among the first to get vaccinated against the coronavirus.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
› Verified 4 days ago
| Entity Name | Ams Northern Indiana Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427619840 PECOS PAC ID: 8022444306 Enrollment ID: O20200205000244 |
News Archive
Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion.
Neuroblastoma is among the most common of childhood cancers and fortunately, some children will get better spontaneously. Yet for children with high-risk disease the outlook is poor: more than half will relapse despite chemotherapy.
Tim Dupin thought — or at least hoped — that Missouri firefighters, paramedics and other emergency medical services personnel would be among the first to get vaccinated against the coronavirus.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Neil J Martin, MD 10706 E Us Highway 36, Avon, IN 46123-7982 Ph: (317) 271-3600 | Neil J Martin, MD 10706 E Us Highway 36, Avon, IN 46123-7982 Ph: (317) 271-3600 |
News Archive
Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion.
Neuroblastoma is among the most common of childhood cancers and fortunately, some children will get better spontaneously. Yet for children with high-risk disease the outlook is poor: more than half will relapse despite chemotherapy.
Tim Dupin thought — or at least hoped — that Missouri firefighters, paramedics and other emergency medical services personnel would be among the first to get vaccinated against the coronavirus.
Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the initiation of a Phase 1 trial of CAL-101, the Company's oral, PI3K delta inhibitor, in combination with standard of care agents Rituxan® (rituximab) and/or Treanda® (bendamustine) in patients with relapsed or refractory indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
› Verified 4 days ago
Dr. Christopher M Doran, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 120 Avon Market Pl Ste 100, Avon, IN 46123 Phone: 317-396-1300 Fax: 317-396-1395 | |
Dr. Andrew Gordon Cook, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 97 Dover St Ste 100, Avon, IN 46123 Phone: 317-706-7246 | |
Dr. Linda Lewis Lister, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 6319 E Us Highway 36, Suite 4, Avon, IN 46123 Phone: 317-345-6348 | |
Ping Fu, MD., PH.D Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1111 Ronald Reagan Pkwy, Avon, IN 46123 Phone: 317-577-4200 Fax: 317-577-9503 | |
Dr. Christopher S Nelson, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 10706 E Us Highway 36, Suite # 7, Avon, IN 46123 Phone: 317-271-3600 Fax: 317-271-3604 | |
Corey Joseph Mitscher, CAA Anesthesiology Medicare: Medicare Enrolled Practice Location: 1111 Ronald Reagan Pkwy, Avon, IN 46123 Phone: 317-217-3000 |